Dr. med. Lars Fransecky

Facts

Phone: +49-431-500-62239
Affiliations: University Medical Centre Schleswig-Holstein (UKSH), Campus Kiel
Address: Arnold-Heller-Str.3, 24105 Kiel

Curriculum Vitae

Education/Training

Since 2019Senior Attending Physician, Dept. of Hematology and Oncology, Christian-Albrechts-University Kiel, Medical Center Schleswig-Holstein, Campus Kiel, Germany
2009-2019Resident, Charite, University Medicine Berlin, Germany
2009Dr. med. (Thesis in medicine), Technical University of Dresden
2002-2009Medical School, Technical University of Dresden, Germany
Medical School, Universidad de Cantabria, Santander, Spain

Research Experience/ Academic Appointments

2022Principal Investigator of an investigator-initiated trial of the German Multicenter Study Group of acute lymphoblastic leukemia: BLIVEN-ALL – An open-label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)
Since 2022Primary Investigator of Deutsche Krebshilfe Grant: Co-targeting of independent apoptosis pathways by Venetoclax and Blinatumomab to overcome treatment resistance in B-cell precursor acute lymphoblastic leukemia
Since 2021Member of the Steering Committee of Study Alliance Leukemia (SAL)
2009-2019Post-doctoral fellow, Charite, University Medicine Berlin, Germany

Project-related publications

Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.

Neumann M, Beder T, Bastian L, Hänzelmann S, Bultmann M, Wolgast N, Hartmann A, Trautmann H, Ortiz-Tanchez J, Schlee C, Schroeder M, Fransecky L, Vosberg S, Fiedler W, Alakel N, Heberling L, Kondakci M, Starck M, Schwartz S, Raffel S, Müller-Tidow C, Schneller F, Reichle A, Burmeister T, Greif PA, Brüggemann M, Gökbuget N, Baldus CD

Leukemia
2024

Participating Institutes